MLICM
IDYA icon

Metropolitan Life Insurance Company (MetLife)’s IDEAYA Biosciences IDYA Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio IDYA Stock Details IDYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,460
Closed -$152K – 1009
2024
Q1 		$152K Buy
3,460
+29
+0.8% +$1.25K 0.01% 829
2023
Q4 		$122K Buy
3,431
+293
+9% +$8.74K 0.01% 968
2023
Q3 		$84.7K Buy
3,138
+170
+6% +$4.31K ﹤0.01% 1100
2023
Q2 		$69.7K Buy
2,968
+638
+27% +$13.1K ﹤0.01% 1220
2023
Q1 		$32K Sell
2,330
-413
-15% -$6.88K ﹤0.01% 1636
2022
Q4 		$49.8K Buy
2,743
+774
+39% +$13K ﹤0.01% 1480
2022
Q3 		$29.4K Hold
1,969
– – ﹤0.01% 1807
2022
Q2 		$27.2K Hold
1,969
– – ﹤0.01% 1886
2022
Q1 		$22K Sell
1,969
-6,374
-76% -$94K ﹤0.01% 2044
2021
Q4 		$197K Hold
8,343
– – ﹤0.01% 2038
2021
Q3 		$213K Hold
8,343
– – ﹤0.01% 2016
2021
Q2 		$175K Buy
8,343
+2,697
+48% +$55.4K ﹤0.01% 2247
2021
Q1 		$133K Buy
+5,646
New +$109K ﹤0.01% 2288

Other funds holding IDYA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s IDYA Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of IDEAYA Biosciences (IDYA) in Q2 2024, closing a stake of 3,460 shares — an estimated $152K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in IDYA in Q1 2021 and held it in 13 quarters. The position peaked at $213K in Q3 2021. 199 funds tracked by Wall St. Rank hold IDYA as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining IDEAYA Biosciences position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 3,460 IDEAYA Biosciences shares in Q2 2024, an estimated $152K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in IDEAYA Biosciences in Q1 2021 and held it in 13 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s IDEAYA Biosciences position peaked at $213K in Q3 2021.
  • 199 funds tracked by Wall St. Rank held IDEAYA Biosciences as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.